



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Roman Reindl-Schwaighofer
roman.reindl-schwaighofer@
meduniwien.ac.at

†These authors share first authorship

SPECIALTY SECTION
This article was submitted to
Nephrology,
a section of the journal
Frontiers in Medicine

RECEIVED 19 September 2022
ACCEPTED 20 September 2022
PUBLISHED 10 October 2022

CITATION
Heinzel A, Schrezenmeier E, Regele F,
Hu K, Raab L, Eder M, Aigner C,
Jabbour R, Aschauer C, Stefanski A-L,
Dörner T, Budde K,
Reindl-Schwaighofer R and
Oberbauer R (2022) Corrigendum:
Three-Month follow-up of
heterologous vs. homologous third
SARS-CoV-2 vaccination in kidney
transplant recipients: Secondary
analysis of a randomized controlled
trial. *Front. Med.* 9:1048395.
doi: 10.3389/fmed.2022.1048395

COPYRIGHT
© 2022 Heinzel, Schrezenmeier,
Regele, Hu, Raab, Eder, Aigner,
Jabbour, Aschauer, Stefanski, Dörner,
Budde, Reindl-Schwaighofer and
Oberbauer. This is an open-access
article distributed under the terms of
the Creative Commons Attribution
License (CC BY). The use, distribution
or reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Three-Month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: Secondary analysis of a randomized controlled trial

Andreas Heinzel^{1†}, Eva Schrezenmeier^{2†}, Florina Regele¹, Karin Hu¹, Lukas Raab¹, Michael Eder¹, Christof Aigner¹, Rhea Jabbour¹, Constantin Aschauer¹, Ana-Luisa Stefanski³, Thomas Dörner³, Klemens Budde², Roman Reindl-Schwaighofer^{1*} and Rainer Oberbauer¹

¹Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

KEYWORDS

COVID-19, kidney transplantation, COVID-19 vaccination, heterologous vaccination, third vaccination

A corrigendum on

[Three-Month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: Secondary analysis of a randomized controlled trial](#)

by Heinzel, A., Schrezenmeier, E., Regele, F., Hu, K., Raab, L., Eder, M., Aigner, C., Jabbour, R., Aschauer, C., Stefanski, A.-L., Dörner, T., Budde, K., Reindl-Schwaighofer, R., and Oberbauer, R. (2022). *Front. Med.* 9:936126. doi: 10.3389/fmed.2022.936126

In the published article, an author name was incorrectly written as “Schretzenmeier.” The correct spelling is “Schrezenmeier.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.